Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef ZakhariaRobert R McWilliamsOlivier RixeJoseph DrabickMontaser F ShaheenKenneth F GrossmannRavindra KolheRafal PacholczykRamses SadekLucinda L TennantChristopher M SmithEugene P KennedyCharles J LinkNicholas N VahanianJiayi YuSteven S ShenErik L BrincksGabriela R RossiDavid MunnMohammed MilhemPublished in: Journal for immunotherapy of cancer (2022)
In this study, the combination of indoximod and (P) was well tolerated and showed antitumor efficacy that is worth further evaluation in selected patients with advanced melanoma.